Jaguar health announces that orphan drug designation application submitted to the fda for crofelemer for a severe congenital diarrheal disorder (cdd) has been accepted for review

Microvillus inclusion disease (mvid), a cdd, is a life-threatening and rare autosomal recessive disease that affects newborns and children and leads to significant morbidity and mortality from severe secretory diarrhea replay link for jaguar's august 22, 2022 investor webcast can be accessed by clicking here ; q2 2022 represented the fourth consecutive quarter of growth in mytesi® net revenue san francisco, ca / accesswire / august 23, 2022 / jaguar health (nasdaq:jagx) today announced that its orphan drug designation (odd) application for crofelemer submitted to the u.s. food and drug administration for a rare congenital diarrheal disorder called microvillus inclusion disease (mvid) has been accepted by the fda for review. a response from the fda on the application is expected by the end of september 2022.
JAGX Ratings Summary
JAGX Quant Ranking